Inhibiteur PKR

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Target IC₅₀: 210 nM inhibiting RNA-induced PKR autophosphorylation and 100 nM in rescuing PKR-dependent translation block

Primary TargetPKR

General description

An imidazolo-oxindole compound that acts as a potent, ATP-binding site directed inhibitor of PKR. Shown to effectively inhibit RNA-induced PKR autophosphorylation (IC₅₀ = 210 nM) and rescue PKR-dependent translation block (IC₅₀ = 100 nM). Shown to increase the late phase of long-lasting synaptic potentiation, and enhance long-term memory in mice. Inactive control is also available (Cat. No. 527455).

An imidazolo-oxindole compound that acts as a potent, ATP-binding site directed inhibitor of PKR. Shown to effectively inhibit RNA-induced PKR autophosphorylation (IC₅₀ = 210 nM) and rescue PKR-dependent translation block (IC₅₀ = 100 nM). Inactive control is also available (Cat. No. 527455). Shown to increase the late phase of long-lasting synaptic potentiation, and enhance long-term memory in mice. Also available as a 50 mM solution in DMSO (Cat. No. 527451).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Zhu, P.J., et al. 2011. Cell147, 1384.Jammi, N.V., et al. 2003. Biochem. Biophys. Res. Commun.308, 50.

Packaging

5 mg in Glass bottle

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Carcinogenic / Teratogenic (D)